Clinical trial
Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor
NCT00314262 · Emory University, Other · Completed
Key facts
| NCT number | NCT00314262 |
|---|---|
| Title | Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor |
| Official title | Phase I/II Study of Chemoprevention With Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Erlotinib (OSI-774, Tarceva) and Cyclooxygenase-2 (COX-2) Inhibitor (Celecoxib) in Premalignant Lesions of Head and Neck of Former Smokers |
| Lead sponsor | Emory University, Other |
| Collaborators | National Institutes of Health (NIH) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Precancerous Conditions |
| Intervention type | Drug |
| Interventions | Erlotinib & Celecoxib |
| Enrollment | 17 |
| Start date | Oct 1, 2006 |
| Primary completion | Nov 1, 2012 |
| Completion | Nov 1, 2012 |
| First posted | Apr 13, 2006 |
| Last update posted | Oct 24, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: